A Comprehensive Literature Review of Treatment of Psoriasis in Patients With Psoriatic Arthritis
Keywords:
Treatment, Psoriasis, Psoriatic ArthritisAbstract
Background: The treatment of psoriasis in patients with psoriatic arthritis (PsA) is a multifaceted challenge that necessitates a comprehensive understanding of the interplay between skin and joint manifestations of the disease, as well as the associated comorbidities. The literature on this topic reveals a progressive evolution in the therapeutic landscape and highlights the complexity of managing PsA effectively. Literature Review: Kingsley and Scott (2015) highlighted the effectiveness of synthetic and biologic disease-modifying antirheumatic drugs (DMARDs) in treating PsA, noting that effective management requires addressing both skin and joint symptoms (H Kingsley & L Scott, 2015). De Marco et al. (2020) explored non-topical treatments for early, untreated psoriatic disease, revealing that while certain pharmacological interventions like apremilast and biologics show promise, there remains a lack of comprehensive composite indices as primary outcome measures. The influence of comorbid conditions on drug choice was further elaborated by Ritchlin et al. (2020), who emphasized the importance of personalized treatment plans tailored to the severity of PsA and the presence of comorbidities (J Mease et al., 2019). Conclusion: In conclusion, the treatment of psoriasis in patients with psoriatic arthritis requires a multifaceted approach that integrates both dermatological and rheumatological considerations, while also addressing the complexities introduced by comorbidities. The literature emphasizes the importance of individualized treatment plans and highlights the need for ongoing research to better understand the interplay between skin and joint symptoms, ultimately aiming for improved patient outcomes.
References
H Kingsley, G. & L Scott, D., 2015. Assessing the effectiveness of synthetic and biologic disease-modifying antirheumatic drugs in psoriatic arthritis – a systematic review. ncbi.nlm.nih.gov
J Mease, P., J Etzel, C., J Huster, W., M Muram, T., W Armstrong, A., R Lisse, J., Rebello, S., Dodge, R., James Murage, M., D Greenberg, J., & N Malatestinic, W., 2019. Understanding the association between skin involvement and joint activity in patients with psoriatic arthritis: experience from the Corrona Registry. ncbi.nlm.nih.gov
De Marco, G., Berekméri, A., C Coates, L., Dubash, S., Emmel, J., D Gladman, D., Lubrano, E., G McGonagle,
D., Mahmood, F., Marchesoni, A., Mason, L., Ogdie, A., Wittmann, M., S Helliwell, P., & Marzo-Ortega, H., 2020. Systematic literature review of non-topical treatments for early, untreated (systemic therapy naïve) psoriatic disease: a GRAPPA initiative. ncbi.nlm.nih.gov
Yu Ting Chia, A., Wei Xin Ang, G., Sook Yee Chan, A., Chan, W., Kit Yeong Chong, T., & Ying Leung, Y., 2021. Managing Psoriatic Arthritis With Inflammatory Bowel Disease and/or Uveitis. ncbi.nlm.nih.gov
Patel, S. & Kumthekar, A., 2021. Psoriatic Arthritis: The Influence of Co-morbidities on Drug Choice. ncbi.nlm.nih.gov
B McInnes, I., M Sawyer, L., Markus, K., LeReun, C., Sabry-Grant, C., & S Helliwell, P., 2022. Targeted systemic therapies for psoriatic arthritis: a systematic review and comparative synthesis of short-term articular, dermatological, enthesitis and dactylitis outcomes. ncbi.nlm.nih.gov
G. Gialouri, C., Evangelatos, G., & E. Fragoulis, G., 2022. Choosing the Appropriate Target for the Treatment of Psoriatic Arthritis: TNFα, IL-17, IL-23 or JAK Inhibitors?. ncbi.nlm.nih.gov
Wang, Y., Zhang, P., Lv, Y., Deng, Y., Yao, M., Wang, L., & Pan, G., 2023. Advancements in the Study of Biologic Agents in Comorbidities of Psoriasis: A Literature Review. ncbi.nlm.nih.gov
Pelechas, E., Kaltsonoudis, E., P. Migkos, M., Koletsos, N., G. Karagianni, P., A. Drosos, A., & V. Voulgari, P., 2024. State of the Art Review on the Treatment of Psoriatic Disease. ncbi.nlm.nih.gov
Downloads
Published
Issue
Section
License
Copyright (c) 2024 Amalia Dwi, Regina, Callista (Author)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Authors publishing here keep copyright but grant the journal first publication rights, under a Creative Commons Attribution-NonCommercial 4.0 License. They can distribute their work non-exclusively elsewhere with an acknowledgment of its first publication in this journal. Posting the work online before and during submission for earlier and greater citation is encouraged, reflecting Open Access benefits.
